Molnex (Morphine Hydrochloride Trihydrate)

Morphine hydrochloride binds to mu‑opioid receptors in the central nervous system, inhibiting the release of neurotransmitters that transmit pain signals. This action reduces the perception of pain and produces sedation, providing effective analgesia for intense or persistent pain conditions.

The dose of Molnex is individualized by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, route of administration, and clinical condition. Healthcare providers determine the appropriate amount, frequency and titration schedule.

The safety of morphine hydrochloride in pregnancy and lactation is not well established. It is classified as a Category unknown drug, and clinicians typically weigh potential benefits against risks before prescribing to pregnant or nursing individuals.

To request Molnex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Molnex delivers morphine, a benchmark opioid with well‑characterized efficacy for severe pain. Compared with newer synthetic opioids, morphine has a longer history of clinical use, a predictable pharmacokinetic profile, and is generally less expensive, though it may have a higher incidence of certain side effects such as constipation.

Molnex should be stored at controlled room temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight and extreme temperatures to maintain sterility and potency.

Molnex is supplied as a sterile injectable solution and can be given via epidural, intramuscular or intrathecal injection. Administration is performed by qualified healthcare professionals following aseptic technique and appropriate dosing guidelines.

The most critical risks include respiratory depression, severe hypotension, and the potential for anaphylactic reactions. Patients should be closely monitored for signs of respiratory compromise, especially during initiation or dose escalation.

Molnex is contraindicated in patients with known hypersensitivity to morphine or any component of the formulation, in those receiving monoamine oxidase inhibitors within 14 days, and in individuals with significant respiratory insufficiency or untreated obstructive sleep apnea.